Latest / The CEO Diary with Fexingo: Leadership Lessons, Executive Decisions, and Corner Office Stories
How Anne Wojcicki Built 23andMe Through Regulatory Fire
In this episode of The CEO Diary, Lucas and Luna explore how Anne Wojcicki built 23andMe from a startup selling $99 DNA tests to a publicly traded biotech company. They focus on the pivotal moment in 2013 when the FDA ordered 23andMe to stop selling its health reports, and how Wojcicki navigated the regulatory storm, kept the company alive, and eventually won FDA approval. The hosts discuss the strategic pivot to drug development, the controversial SPAC merger, and the tensions between consumer genetics and medical regulation. A case study in regulatory grit and long-term vision…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.